| 000 | 01154 a2200277 4500 | ||
|---|---|---|---|
| 005 | 20250517015728.0 | ||
| 264 | 0 | _c20160317 | |
| 008 | 201603s 0 0 eng d | ||
| 022 | _a1463-1326 | ||
| 024 | 7 |
_a10.1111/dom.12451 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSharma, M D | |
| 245 | 0 | 0 |
_aPotential for combination of dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors for the treatment of type 2 diabetes. _h[electronic resource] |
| 260 |
_bDiabetes, obesity & metabolism _cJul 2015 |
||
| 300 |
_a616-21 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 |
_aBlood Glucose _xdrug effects |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xblood |
| 650 | 0 | 4 |
_aDipeptidyl-Peptidase IV Inhibitors _xtherapeutic use |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 |
_aGlycated Hemoglobin _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aSodium-Glucose Transporter 2 Inhibitors |
| 773 | 0 |
_tDiabetes, obesity & metabolism _gvol. 17 _gno. 7 _gp. 616-21 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/dom.12451 _zAvailable from publisher's website |
| 999 |
_c24632051 _d24632051 |
||